ArticleInternational journal of molecular sciences2024
Nucleus Accumbens Associated Protein 1 in Cancers-The Real Value.
Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NAC1/ACOX2 Axis as a Novel Therapeutic Target for Endometriosis-Related Ovarian Neoplasms.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant tumors are a leading cause of death worldwide, second only to cardiovascular disease. They occur in every population and have a high risk of mortality. The etiopathogenesis of malignant tumors is diverse and there are still many unknowns, leading to huge diagnostic and therapeutic challenges. Therefore, the search for ideal diagnostic and therapeutic agents is ongoing. One of the promising factors affecting cancer is the nucleus accumbens associated protein 1 (NACC1). It is a transcriptional coregulator. Moreover, it plays a multifaceted role in promoting tumorigenesis. NACC1 expression analyses were performed using The Cancer Genome Atlas (TCGA) data accessed from the University of Alabama at Birmingham Cancer (UALCAN) database, and the expression data were interconnected with clinicopathological parameters. All statistical analyses were conducted using GraphPad Prism and Statistica. The results revealed that NACC1 was expressed in almost all of the analyzed cancers, and its expression level correlates with different clinicopathological parameters. This study demonstrates that NACC1 is potentially involved in the pathogenesis, invasion, and immune response associated with many cancers. However, NACC1 is not a suitable candidate as a diagnostic biomarker as it is not specific for any type of malignancy and there are discrepancies in its expression in relation to many clinicopathological parameters. The implementation of NACC1 as a therapeutic target may improve the effectiveness of cancer treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.